Navigation Links
Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
Date:12/7/2011

BLUE BELL, Pa., Dec. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that it has closed an underwritten public offering of 7,699,712 shares of its common stock and warrants to purchase up to 5,774,784 additional shares of its common stock, which included the partial exercise of the underwriter's overallotment option to purchase additional units at the public offering price. The shares and warrants were placed with five institutional investors. These securities were sold in units, consisting of one share of common stock and 0.75 of a warrant to purchase one share of common stock, at a price of $0.5195 per unit. The warrants have a term of five years and an exercise price of $0.65 per share. Inovio may call these warrants if the closing bid price of the common stock has been at least $1.30 over 20 trading daysand certain other conditions are met.

The gross proceeds of the offering were $4.0 million. Net proceeds to Inovio, after deducting the underwriter's discounts and other estimated offering expenses payable by Inovio, were approximately $3.7 million. Brean Murray, Carret & Co. acted as sole bookrunner of this offering. Inovio intends to use the net proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, said "We're pleased to see these institutional investors support our strategy to develop Inovio's synthetic vaccines.  In 2011 we achieved multiple important milestones toward our goal of revolutionizing vaccine technology and we look forward to the clinical outcomes ahead of us in 2012."

The securities described above were offered by Inovio pursuant to a registration statement previously fil
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
2. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
3. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
4. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
5. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
6. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
7. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
8. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
9. Inovio Pharmaceuticals to Present at Investor Conferences
10. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
11. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Releases ... ,Friendly Aedes aegypti , , reduced the ... Brazil by 95%, well below the ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected ... of Oxitec,s genetically engineered mosquitoes. The results showed that ...
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
(Date:7/2/2015)... N.C. , July 2, 2015 ... assets related to the ion channel biology platform from ... been obtained as part of Pfizer,s 2011 acquisition of ... rights to the "Icagen" name and trademark.  XRPro Sciences ... services for ion channel and transporter drug discovery, combining ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
(Date:7/3/2015)... Greenville, SC (PRWEB) , ... ... ... Society has announced the sessions and speaker lineup for its 2015 ... nursing, taking place August 6-8, 2015 at the Renaissance Orlando at SeaWorld ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers ... minimal asbestos exposure. Click here to read the complete story , just posted ... Center, Cedars Sinai Medical Center, and New York University exposed mice with a mutation ...
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich , ... held from March 4th - 6th, the 2016 (a previous announcement had stated the ... to take participants from the basic training and fundamentals of nasal surgery through the ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national president recruitment for Regional Care, Inc. in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... of the top-ranked executive search firms in the healthcare industry, B. E. Smith ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... ... the emerging medical travel space, announced that international medical quality authority, Dr. David Jaimovich, ... ... Satori World Medical, a leading global healthcare company specializing in the emerging medical travel ...
... smoke are at risk of lung cancer , THURSDAY, Dec. ... of malignancies caused by smoking, with a new study strengthening ... providing more bad news for people who haven,t managed to ... Epidemiology, Biomarkers & Prevention , a themed issue on tobacco, ...
... , Diabetes: A ... Hands-on Experience for All Ages , DETROIT, Dec. 3 ... seconds. On December 5, 2009, the Detroit Science Center will debut its ... that the public might have about diabetes, diabetes treatment and the role ...
... , HOUSTON, Dec. 3 Three US Oncology, Inc ... the Occupational Safety & Health category from the National ... Specialty, LP ; US Oncology Clinical & Research Pharmacy distribution ... have continuously received the Occupational Excellence Award from the national ...
... protected volunteers from virus linked to cervical cancer , WEDNESDAY, ... Cervarix protects women from infection for longer than six years, ... two types of HPV (HPV-16 and HPV-18) most commonly associated ... women, aged 15 to 25, with a normal cervical profile ...
... , Unfair Labor Practices, Protecting Donors, and ... Teamsters who work at American Red Cross (ARC) Blood ... protest unfair labor practices and problems with working conditions at ... the integrity of the blood supply, not to mention the ...
Cached Medicine News:Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 2Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 3Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 4Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:US Oncology Celebrates Consecutive Safety 2Health News:US Oncology Celebrates Consecutive Safety 3Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Philadelphia Red Cross Blood Workers Strike to Protect Donor and Blood Safety 2
... million people are diagnosed with varicose veins ... patients never seek treament and are apprehensive ... offer them an effective alternative to conventional ... or hook phlebectomy), is considered a laborious ...
...
Inquire...
Inquire...
Medicine Products: